OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 31
Laurie P. Volak, Heide Marika Duevel, Sara C. Humphreys, et al.
Drug Metabolism and Disposition (2023) Vol. 51, Iss. 7, pp. 792-803
Closed Access | Times Cited: 31
Showing 1-25 of 31 citing articles:
Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Keith R. Hornberger, Erika Araujo
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 8281-8287
Open Access | Times Cited: 68
Exploring the chemical space of orally bioavailable PROTACs
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Giulia Apprato, Vasanthanathan Poongavanam, Diego García Jiménez, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 4, pp. 103917-103917
Open Access | Times Cited: 17
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Innovative, combinatorial and high-throughput approaches to degrader synthesis
Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 10, pp. 4838-4861
Closed Access | Times Cited: 9
Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 10, pp. 4838-4861
Closed Access | Times Cited: 9
Modulating the phosphorylation status of target proteins through bifunctional molecules
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Qindi He, Zhijie Wang, Rongrong Wang, et al.
Drug Discovery Today (2025), pp. 104307-104307
Closed Access | Times Cited: 1
Application of machine learning models for property prediction to targeted protein degraders
Giulia Peteani, Minh Huynh, Grégori Gerebtzoff, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Giulia Peteani, Minh Huynh, Grégori Gerebtzoff, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
Sandra Kuemper, Andrew G. Cairns, Kristian Birchall, et al.
Frontiers in Molecular Neuroscience (2024) Vol. 17
Open Access | Times Cited: 6
IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs
Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11421-11434
Closed Access | Times Cited: 6
Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11421-11434
Closed Access | Times Cited: 6
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Donglu Zhang, Bin Ma, Peter S. Dragovich, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 5
Donglu Zhang, Bin Ma, Peter S. Dragovich, et al.
Communications Medicine (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 5
PK/PD modeling of targeted protein degraders: Charting new waters and navigating the shallows
Robin Thomas Ulrich Haid, Andreas Reichel
Drug Discovery Today (2025), pp. 104311-104311
Open Access
Robin Thomas Ulrich Haid, Andreas Reichel
Drug Discovery Today (2025), pp. 104311-104311
Open Access
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©
Christine K. Maurer, Zhizhou Fang, Christina Schindler, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Christine K. Maurer, Zhizhou Fang, Christina Schindler, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Applications of Contemporary Tools to Measure Plasma Protein Binding of Targeted Protein Degraders
Mark Niosi, Sam Zhang, Woodrow Burchett, et al.
Drug Metabolism and Disposition (2025), pp. 100066-100066
Closed Access
Mark Niosi, Sam Zhang, Woodrow Burchett, et al.
Drug Metabolism and Disposition (2025), pp. 100066-100066
Closed Access
Transforming the Discovery of Targeted Protein Degraders: The Translational Power of Predictive PK /PD Modeling
Robin Thomas Ulrich Haid, Andreas Reichel
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 770-781
Open Access | Times Cited: 3
Robin Thomas Ulrich Haid, Andreas Reichel
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 770-781
Open Access | Times Cited: 3
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders
Michelle Hemkens, Katie Stamp, Lise I. Loberg, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103643-103643
Closed Access | Times Cited: 8
Michelle Hemkens, Katie Stamp, Lise I. Loberg, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 8, pp. 103643-103643
Closed Access | Times Cited: 8
In silico ADME/tox comes of age: twenty years later
Sean Ekins, Thomas R. Lane, Fabio Urbina, et al.
Xenobiotica (2023) Vol. 54, Iss. 7, pp. 352-358
Closed Access | Times Cited: 7
Sean Ekins, Thomas R. Lane, Fabio Urbina, et al.
Xenobiotica (2023) Vol. 54, Iss. 7, pp. 352-358
Closed Access | Times Cited: 7
PROTACs reach clinical development in inflammatory skin disease
Fleur M. Ferguson
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3006-3007
Closed Access | Times Cited: 7
Fleur M. Ferguson
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3006-3007
Closed Access | Times Cited: 7
Property-based optimisation of PROTACs
James S. Scott, Iacovos N. Michaelides, Markus Schade
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
James S. Scott, Iacovos N. Michaelides, Markus Schade
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia
Jamie Jarusiewicz, Satoshi Yoshimura, Marisa Actis, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Jamie Jarusiewicz, Satoshi Yoshimura, Marisa Actis, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic
Jaydeep Yadav, Benjamin J. Maldonato, Joseph M. Roesner, et al.
Drug Metabolism Reviews (2024), pp. 1-33
Closed Access | Times Cited: 1
Jaydeep Yadav, Benjamin J. Maldonato, Joseph M. Roesner, et al.
Drug Metabolism Reviews (2024), pp. 1-33
Closed Access | Times Cited: 1
Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
Yue Wu, Bernd Meibohm, Taichang Zhang, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Yue Wu, Bernd Meibohm, Taichang Zhang, et al.
British Journal of Pharmacology (2024)
Open Access | Times Cited: 1
Impact of Linker Composition on VHL PROTAC Cell Permeability
Yordanos Esubalew Abeje, Lianne H. E. Wieske, Vasanthanathan Poongavanam, et al.
Journal of Medicinal Chemistry (2024)
Open Access | Times Cited: 1
Yordanos Esubalew Abeje, Lianne H. E. Wieske, Vasanthanathan Poongavanam, et al.
Journal of Medicinal Chemistry (2024)
Open Access | Times Cited: 1
The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
Scott A. Hollingsworth, S.A. Johnson, Pouyan Khakbaz, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 7, pp. 1294-1314
Closed Access | Times Cited: 3
Scott A. Hollingsworth, S.A. Johnson, Pouyan Khakbaz, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 7, pp. 1294-1314
Closed Access | Times Cited: 3
Metabolism of new drug modalities research advances – 2023 year in review
Bin Ma, Upendra A. Argikar, Lionel Cheruzel, et al.
Drug Metabolism Reviews (2024), pp. 1-24
Closed Access
Bin Ma, Upendra A. Argikar, Lionel Cheruzel, et al.
Drug Metabolism Reviews (2024), pp. 1-24
Closed Access
